Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Alzheimers Dis ; 32(4): 949-67, 2012.
Article in English | MEDLINE | ID: mdl-22903131

ABSTRACT

Latrepirdine (Dimebon), an anti-histamine, has shown some benefits in trials of neurodegenerative diseases characterized by accumulation of aggregated or misfolded protein such as Alzheimer's disease (AD) and has been shown to promote the removal of α-synuclein protein aggregates in vivo. An important pathway for removal of aggregated or misfolded proteins is the autophagy-lysosomal pathway, which has been implicated in AD pathogenesis, and enhancing this pathway has been shown to have therapeutic potential in AD and other proteinopathies. Here we use a yeast model, Saccharomyces cerevisiae, to investigate whether latrepirdine can enhance autophagy and reduce levels of amyloid-ß (Aß)42 aggregates. Latrepirdine was shown to upregulate yeast vacuolar (lysosomal) activity and promote transport of the autophagic marker (Atg8) to the vacuole. Using an in vitro green fluorescent protein (GFP) tagged Aß yeast expression system, we investigated whether latrepirdine-enhanced autophagy was associated with a reduction in levels of intracellular GFP-Aß42. GFP-Aß42 was localized into punctate patterns compared to the diffuse cytosolic pattern of GFP and the GFP-Aß42 (19:34), which does not aggregate. In the autophagy deficient mutant (Atg8Δ), GFP-Aß42 showed a more diffuse cytosolic localization, reflecting the inability of this mutant to sequester GFP-Aß42. Similar to rapamycin, we observed that latrepirdine significantly reduced GFP-Aß42 in wild-type compared to the Atg8Δ mutant. Further, latrepirdine treatment attenuated Aß42-induced toxicity in wild-type cells but not in the Atg8Δ mutant. Together, our findings provide evidence for a novel mechanism of action for latrepirdine in inducing autophagy and reducing intracellular levels of GFP-Aß42.


Subject(s)
Amyloid beta-Peptides/antagonists & inhibitors , Autophagy/physiology , Green Fluorescent Proteins/metabolism , Indoles/pharmacology , Intracellular Fluid/metabolism , Peptide Fragments/antagonists & inhibitors , Saccharomyces cerevisiae/metabolism , Amyloid beta-Peptides/metabolism , Autophagy/drug effects , Down-Regulation/drug effects , Green Fluorescent Proteins/antagonists & inhibitors , Humans , Intracellular Fluid/drug effects , Peptide Fragments/metabolism , Saccharomyces cerevisiae/cytology , Saccharomyces cerevisiae/drug effects , Up-Regulation/drug effects
2.
Biochem Biophys Res Commun ; 409(3): 477-82, 2011 Jun 10.
Article in English | MEDLINE | ID: mdl-21600886

ABSTRACT

This study has found that the Maltose binding protein Aß42 fusion protein (MBP-Aß42) forms soluble oligomers while the shorter MBP-Aß16 fusion and control MBP did not. MBP-Aß42, but neither MBP-Aß16 nor control MBP, was toxic in a dose-dependent manner in both yeast and primary cortical neuronal cells. This study demonstrates the potential utility of MBP-Aß42 as a reagent for drug screening assays in yeast and neuronal cell cultures and as a candidate for further Aß42 characterization.


Subject(s)
Amyloid beta-Peptides/chemistry , Amyloid beta-Peptides/toxicity , Neurons/drug effects , Peptide Fragments/chemistry , Peptide Fragments/toxicity , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/toxicity , Amyloid beta-Peptides/genetics , Animals , Apoptosis , Cerebral Cortex/cytology , Maltose-Binding Proteins/chemistry , Maltose-Binding Proteins/genetics , Maltose-Binding Proteins/toxicity , Mice , Peptide Fragments/genetics , Protein Multimerization , Recombinant Fusion Proteins/genetics , Saccharomyces cerevisiae/drug effects , Solubility
3.
Nature ; 443(7108): 218-21, 2006 Sep 14.
Article in English | MEDLINE | ID: mdl-16957736

ABSTRACT

The insulin receptor is a phylogenetically ancient tyrosine kinase receptor found in organisms as primitive as cnidarians and insects. In higher organisms it is essential for glucose homeostasis, whereas the closely related insulin-like growth factor receptor (IGF-1R) is involved in normal growth and development. The insulin receptor is expressed in two isoforms, IR-A and IR-B; the former also functions as a high-affinity receptor for IGF-II and is implicated, along with IGF-1R, in malignant transformation. Here we present the crystal structure at 3.8 A resolution of the IR-A ectodomain dimer, complexed with four Fabs from the monoclonal antibodies 83-7 and 83-14 (ref. 4), grown in the presence of a fragment of an insulin mimetic peptide. The structure reveals the domain arrangement in the disulphide-linked ectodomain dimer, showing that the insulin receptor adopts a folded-over conformation that places the ligand-binding regions in juxtaposition. This arrangement is very different from previous models. It shows that the two L1 domains are on opposite sides of the dimer, too far apart to allow insulin to bind both L1 domains simultaneously as previously proposed. Instead, the structure implicates the carboxy-terminal surface of the first fibronectin type III domain as the second binding site involved in high-affinity binding.


Subject(s)
Protein Folding , Receptor, Insulin/chemistry , Receptor, Insulin/metabolism , Crystallography, X-Ray , Dimerization , Immunoglobulin Fab Fragments/immunology , Microscopy, Electron , Models, Molecular , Protein Structure, Quaternary , Protein Structure, Tertiary , Receptor, Insulin/immunology , Receptor, Insulin/ultrastructure
SELECTION OF CITATIONS
SEARCH DETAIL
...